{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:13:39Z","timestamp":1780337619519,"version":"3.54.1"},"reference-count":28,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by widespread fibrosis, including skin thickening. Mycophenolate mofetil (MMF) is commonly used in SSc-associated interstitial lung disease, but its efficacy in improving skin fibrosis has not been systematically evaluated. This study aimed to assess the therapeutic effect of MMF on cutaneous sclerosis in SSc, as measured by the modified Rodnan skin score (mRSS). Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, Embase, and Web of Science were searched from January 2000 to March 2025. Studies reporting mRSS outcomes in SSc patients treated with MMF were included, provided that the effect of MMF could be separately evaluated when used alongside other therapies. Risk of bias was assessed using the Cochrane RoB 2.0 tool for randomized controlled trials and the ROBINS-I tool for non-randomized studies. A random-effects model was used to estimate the pooled mean change in mRSS. Heterogeneity and publication bias were evaluated. Results: Eight studies involving 569 patients were included. The pooled mean reduction in mRSS following MMF treatment was \u22125.82 (95% CI: \u22127.46 to \u22124.19), exceeding the minimal clinically important difference. Heterogeneity across studies was substantial (I2 = 82.6%). A post hoc exploratory subgroup analysis suggested greater improvement in early disease (&lt;2 years), though this finding requires confirmation in prospective studies. MMF was generally well tolerated, with low discontinuation rates due to adverse events. Conclusions: MMF is associated with a statistically and clinically significant improvement in skin fibrosis in patients with SSc. These findings support its use as a frontline therapy for progressive cutaneous involvement, although further prospective studies are needed to identify optimal candidates for treatment.<\/jats:p>","DOI":"10.3390\/jcm14124187","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:44:23Z","timestamp":1749714263000},"page":"4187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-091X","authenticated-orcid":false,"given":"Ryuichi","family":"Ohta","sequence":"first","affiliation":[{"name":"Department of Community Care, Unman City Hospital, Unnan 699-1221, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Horinishi","sequence":"additional","affiliation":[{"name":"Heisei Memorial Hospital, Unnan 690-2404, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-5161","authenticated-orcid":false,"given":"Chiaki","family":"Sano","sequence":"additional","affiliation":[{"name":"Community Medicine Management, Shimane University Faculty of Medicine, Izumo 693-8501, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8794-7106","authenticated-orcid":false,"given":"Kunihiro","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shimane University Faculty of Medicine, Izumo 693-8501, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12016-022-08929-x","article-title":"A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis","volume":"64","author":"Lazzaroni","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Della Casa, G., Salvarani, C., and Manfredi, A. (2020). Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrat. Rev. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020407"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4078\/jrd.2024.0129","article-title":"Pathogenesis of systemic sclerosis: An integrative review of recent advances","volume":"32","author":"Son","year":"2025","journal-title":"J. Rheum Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.resinv.2024.11.003","article-title":"Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil","volume":"62","author":"Takada","year":"2024","journal-title":"Respir. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Luo, X., Deng, Q., Xue, Y., Zhang, T., Wu, Z., Peng, H., Xuan, L., and Pan, G. (2021). Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-\u03b2RI\/Smad Signaling. Molecules, 26.","DOI":"10.3390\/molecules26061715"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1046\/j.1600-6135.2003.00244.x","article-title":"Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity","volume":"3","author":"Shihab","year":"2003","journal-title":"Am. J. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/rheumatology\/keae517","article-title":"Mycophenolate mofetil directly modulates myeloid viability and pro-fibrotic activation of human macrophages","volume":"64","author":"Morris","year":"2025","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17534666221117002","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"Luppi","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann. Rheum Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"Int. J. Rheum Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses from Two Randomized Placebo-Controlled Trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: A double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1093\/rheumatology\/keab931","article-title":"Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies","volume":"61","author":"Yomono","year":"2022","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1002\/acr2.70004","article-title":"Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis","volume":"7","author":"White","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD-achievements and ambiguity in a devastating disease","volume":"21","author":"Allanore","year":"2020","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/1756-185X.12399","article-title":"Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series","volume":"17","author":"Yilmaz","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/acr2.11165","article-title":"Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study","volume":"2","author":"Mihai","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.semarthrit.2019.09.019","article-title":"Challenges in systemic sclerosis trial design","volume":"49","author":"Denton","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: An unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/21678707.2016.1114454","article-title":"Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives","volume":"4","author":"Mendoza","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e000260","DOI":"10.1136\/rmdopen-2016-000260","article-title":"Treatment of systemic sclerosis: Is there any hope for the future?","volume":"2","author":"Allanore","year":"2016","journal-title":"RMD Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1759720X211066686","DOI":"10.1177\/1759720X211066686","article-title":"The role of antifibrotic therapies in the treatment of systemic sclerosis\u2013associated interstitial lung disease","volume":"14","author":"Boleto","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/ard.45.5.384","article-title":"Regressive systemic sclerosis","volume":"45","author":"Black","year":"1986","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:50:51Z","timestamp":1760032251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14124187"],"URL":"https:\/\/doi.org\/10.3390\/jcm14124187","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}